MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414575 | Name: Rigosertib Free Base
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rigosertib Free Base is a Plk1 inhibitor with antineoplastic activity.

Chemical Structure

Rigosertib Free Base
Rigosertib Free Base
CAS#592542-59-1 (free base)

Theoretical Analysis

MedKoo Cat#: 414575

Name: Rigosertib Free Base

CAS#: 592542-59-1 (free base)

Chemical Formula: C21H25NO8S

Exact Mass: 451.1301

Molecular Weight: 451.49

Elemental Analysis: C, 55.87; H, 5.58; N, 3.10; O, 28.35; S, 7.10

Price and Availability

Size Price Availability Quantity
25mg USD 450.00 2 Weeks
50mg USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
592542-59-1 (free base) 1225497-78-8 (sodium) 592542-60-4 (sodium)
Synonym
Rigosertib Free Base; ON01910; ON-01910; ON 01910
IUPAC/Chemical Name
Glycine, N-(2-methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl) methyl)phenyl)-
InChi Key
OWBFCJROIKNMGD-BQYQJAHWSA-N
InChi Code
InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+
SMILES Code
O=C(O)CNC1=CC(CS(=O)(/C=C/C2=C(OC)C=C(OC)C=C2OC)=O)=CC=C1OC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 451.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Jost M, Chen Y, Gilbert LA, Horlbeck MA, Krenning L, Menchon G, Rai A, Cho MY, Stern JJ, Prota AE, Kampmann M, Akhmanova A, Steinmetz MO, Tanenbaum ME, Weissman JS. Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent. Mol Cell. 2020 Jul 2;79(1):191-198.e3. doi: 10.1016/j.molcel.2020.06.008. PMID: 32619469; PMCID: PMC7332992. 2: Jost M, Chen Y, Gilbert LA, Horlbeck MA, Krenning L, Menchon G, Rai A, Cho MY, Stern JJ, Prota AE, Kampmann M, Akhmanova A, Steinmetz MO, Tanenbaum ME, Weissman JS. Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent. Mol Cell. 2017 Oct 5;68(1):210-223.e6. doi: 10.1016/j.molcel.2017.09.012. PMID: 28985505; PMCID: PMC5640507. 3: Baker SJ, Cosenza SC, Athuluri-Divakar S, Reddy MVR, Vasquez-Del Carpio R, Jain R, Aggarwal AK, Reddy EP. A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding Agent. Mol Cell. 2020 Jul 2;79(1):180-190.e4. doi: 10.1016/j.molcel.2020.05.024. PMID: 32619468. 4: Kowalczyk JT, Wan X, Hernandez ER, Luo R, Lyons GC, Wilson KM, Gallardo DC, Isanogle KA, Robinson CM, Mendoza A, Heske CM, Chen JQ, Luo X, Kelly AE, Difilippantinio S, Robey RW, Thomas CJ, Sackett DL, Morrison DK, Randazzo PA, Jenkins LMM, Yohe ME. Rigosertib Induces Mitotic Arrest and Apoptosis in RAS- Mutated Rhabdomyosarcoma and Neuroblastoma. Mol Cancer Ther. 2021 Feb;20(2):307-319. doi: 10.1158/1535-7163.MCT-20-0525. Epub 2020 Nov 6. PMID: 33158997; PMCID: PMC7867632. 5: Balaian E, Weidner H, Wobus M, Baschant U, Jacobi A, Mies A, Bornhäuser M, Guck J, Hofbauer LC, Rauner M, Platzbecker U. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes. Ann Hematol. 2019 Sep;98(9):2063-2072. doi: 10.1007/s00277-019-03756-1. Epub 2019 Jul 16. PMID: 31312928. 6: Günther JK, Nikolajevic A, Ebner S, Troppmair J, Khalid S. Rigosertib- Activated JNK1/2 Eliminate Tumor Cells through p66Shc Activation. Biology (Basel). 2020 May 15;9(5):99. doi: 10.3390/biology9050099. PMID: 32429320; PMCID: PMC7284707. 7: Navada SC, Silverman LR. The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther. 2016 Aug;16(8):805-10. doi: 10.1080/14737140.2016.1209413. Epub 2016 Jul 15. PMID: 27400247. 8: Atanasova VS, Pourreyron C, Farshchian M, Lawler M, Brown CA 4th, Watt SA, Wright S, Warkala M, Guttmann-Gruber C, Hofbauer JP, Fuentes I, Prisco M, Rashidghamat E, Has C, Salas-Alanis JC, Palisson F, Hovnanian A, McGrath JA, Mellerio JE, Bauer JW, South AP. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma. Clin Cancer Res. 2019 Jun 1;25(11):3384-3391. doi: 10.1158/1078-0432.CCR-18-2661. Epub 2019 Mar 7. PMID: 30846478; PMCID: PMC8185613. 9: Rahmani F, Asgharzadeh F, Avan A, Barneh F, Parizadeh MR, Ferns GA, Ryzhikov M, Ahmadian MR, Giovannetti E, Jafari M, Khazaei M, Hassanian SM. Rigosertib potently protects against colitis-associated intestinal fibrosis and inflammation by regulating PI3K/AKT and NF-κB signaling pathways. Life Sci. 2020 May 15;249:117470. doi: 10.1016/j.lfs.2020.117470. Epub 2020 Mar 2. PMID: 32135184. 10: Navada SC, Garcia-Manero G, OdchimarReissig R, Pemmaraju N, Alvarado Y, Ohanian MN, John RB, Demakos EP, Zbyszewski PS, Maniar M, Woodman RC, Fruchtman SM, Silverman LR. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. Leuk Res. 2020 Jul;94:106369. doi: 10.1016/j.leukres.2020.106369. Epub 2020 May 12. PMID: 32442785.